SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and downward pressure as investors react to a double miss in its earnings report, fueling intense community debate regarding the company's long-term growth and the impact of its recent strategic shifts. While some shareholders are capitalizing on the depressed price as a buying opportunity, others are expressing deep frustration and loss of confidence in management, creating a contentious atmosphere among those holding the stock versus those anticipating further declines.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is currently facing intense volatility as the market reacts to shifting ad-tech sector sentiment, with community members deeply divided over whether the stock is a deep value opportunity or trapped in a permanent downward spiral. Investors are laser-focused on upcoming earnings and potential management pivots, debating the impact of competitive headwinds from tech giants against the company's strong balance sheet and high client retention.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense social media discussion as traders react to a strong quarterly earnings report featuring record revenue growth and raised forward guidance. The community is actively debating the potential for a massive short squeeze, with many retail investors citing high short interest and institutional accumulation as primary catalysts for a sustained rally, while skeptics remain focused on the company's path to consistent profitability.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing intense volatility as investors react to the first major share lockup expiry, which has ignited a battle between shorts anticipating a massive sell-off and bulls who are treating the current dip as a buying opportunity. The community remains deeply divided, with many debating whether the stock's long-term growth potential and Terafab developments outweigh the risks posed by potential insider selling and significant share dilution.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending after reporting record quarterly revenue that significantly exceeded analyst expectations, further fueled by improving gross margins and strong patient adoption of its cell therapy. Investors are actively discussing the company's upward momentum in clinical trial progress, potential for upward guidance revisions, and ongoing speculation regarding a future buyout.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is facing extreme volatility after reporting a mixed second quarter, where a slight revenue miss and softer-than-expected guidance triggered a sharp selloff despite strong year-over-year growth. The community is deeply divided, with some investors panic-selling while others view the sudden drop as a significant buying opportunity for a cash-flow-positive company.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently trending as investors react to strong institutional accumulation, including significant insider buying by leadership, and a breakout driven by optimism over the company's margin recovery and 2026 growth outlook. Community discussion is heavily focused on the stock's impressive multi-bagger performance and the potential for a long-term re-rating as the company demonstrates scaling success and operating leverage in the ACA market.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is experiencing significant volatility following a post-earnings sell-off that has traders debating whether the stock is a high-quality compounder or an overvalued software name. The community is actively discussing heavy insider selling and the impact of the company's competition with Motorola, while investors weigh the long-term potential of its AI and public safety software suite against current market headwinds.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense community debate as investors weigh the company's aggressive store expansion and recent acquisition of distressed assets against concerns over its high valuation multiples. While some bulls emphasize strong customer loyalty and the long-term potential of its footprint growth, skeptics remain cautious, highlighting the pressure on margins and the stock's elevated price-to-earnings ratio compared to industry peers.

Chime Financial, Inc. engages in the design and development of a digital banking application. Its mobile app, Chime, provides online banking, fee-free overdraft, mobile banking, automatic savings, mobile payments, and security and control capabilities. The company was founded by Christopher R. Britt and Ryan King in 2012 and is headquartered in San Francisco, CA.

Chime Financial Inc - Ordinary Shares - Class A

Chime Financial, Inc.

Chime Financial is facing significant volatility as investors weigh strong revenue growth and recent earnings beats against a steep decline from its IPO highs. Community sentiment remains polarized, with many retail traders expressing frustration over the persistent downtrend while some are actively debating whether current valuation levels present an opportunistic entry point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher

PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

Equity

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

$PDSB Q1 '26 Earnings Results & Recap

Reported GAAP EPS of -$0.13 up 38.10% YoY

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PDSBPDS Biotechnology Corporation

Fundamentals

Connect Stocktwits to ChatGPT

Latest PDSB News